Calliditas Therapeutics présente des analyses de données supplémentaires de l'essai de phase 3 NeflgArd sur Nefecon dans la néphropathie primaire à IgA au Congrès mondial de néphrologie de l'ISN 2024
Calliditas Therapeutics présente des analyses de données supplémentaires de l'essai de phase 3 NeflgArd sur Nefecon dans la néphropathie primaire à IgA au Congrès mondial de néphrologie de l'ISN 2024
PR Newswire
STOCKHOLM, le 18 avril 2024
STOCKHOLM, 18 avril 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq : CALT) (Nasdaq Stockholm : CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentine on 13. – 16. Avril 2024.
"We were pleased to share additional analyses from the 2-year Phase 3 NeflgArd trial of Nefecon in IgAN at this year's World Congress of Nephrology," said Richard Philipson, Chief Medical Officer of Calliditas. "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."
Poster presentation details are below and will be available on the Presentations and Publications page on the Calliditas' corporate website following the meeting.
Poster Presentation Analyses:
Poster Title: "Nefecon treatment provides kidney benefits for patients with IgAN that extend to those with low levels of UPCR: A sub-analysis of the phase III NefIgArd trial"
An extended analysis of patients with baseline UPCR levels above and below 0.8 g/g was performed to further explore the potential benefits of Nefecon. In the full analysis involving 364 patients regardless of baseline UPCR, Nefecon treatment consistently improved the estimated glomerular filtrate rate (eGFR) over the 2-year study period compared to placebo. 72 patients with a baseline UPCR <0.8 g/g experienced sustained eGFR improvement (p=0.0026), which persisted for up to 18 months after treatment initiation, even after the treatment cessation at month 9. Those patients also achieved an eGFR slope of -0.25 mL/min/1.732 per year, indicating that Nefecon treatment may support them in reaching the RaDaR treatment target of an eGFR decline of <1 mL/min/1.73 m2 per year. This objective is pivotal in mitigating the risk of kidney failure in their lifetime.
Poster Title: "eGFR decline in patients with IgAN treated with Nefecon or placebo: Results from the 2-year NefIgArd Phase 3 trial"
During the 9-month treatment period, Nefecon showed a 30% reduction in UPCR compared to the placebo, sustained for 2 years. The percentage of patients with a confirmed 30% reduction in eGFR or kidney failure was lower in the Nefecon arm compared to placebo, and the time to such events was significantly delayed with Nefecon (hazard ratio [HR] 0.45; 95% confidence interval 0.26, 0.75]; p=0.0014 [1-sided]). Supplementary analysis with rescue medication yielded similar results, irrespective of the handling of rescue medication: Rescue medication counted as an event: HR 0.51 (95% CI 0.33, 0.79), Regardless of rescue medication: HR 0.44 (95% CI 0.27, 0.71). The treatment effect of Nefecon on the risk of kidney function decline was consistent regardless of baseline UPCR. These findings strongly suggest preserved kidney function and provide support for Nefecon as a disease-modifying therapy in patients with IgAN.
Poster Title: Nefecon effect on quality of life in patients with IgAN: SF-36 results from the Phase 3 NefIgArd trial"
The 2-year results of quality of life (QoL) analyses based on 36-Item Short Form Survey (SF-36) assessments at 9 and 24 months revealed no meaningful differences in any QoL domain between Nefecon and placebo groups after 9 months of treatment. These SF-36 scores remained consistent after 15 months of off-drug observational follow-up further supporting the benefit/risk profile of Nefecon.
Poster Title: "Nefecon treatment response in Asian and White patient populations with immunoglobulin A nephropathy: A 2-year analysis of the Phase 3 NefIgArd trial"
The responses to Nefecon treatment from the full 2-year NefIgArd trial were assessed in patients identifying as Asian (n=83) or White (n=275). Regardless of race and ethnicity, Nefecon showed a favorable change in eGFR compared to placebo of 5.5 mL/min/1.732 in Asian patients and 4.8 mL/min/1.732 in White patients. Nefecon also demonstrated greater reductions in UPCR at 9 and 24 months with notable delays in kidney function decline events. These effects were consistent across races and ethnicities. Additionally, Nefecon significantly reduced the rate of microhematuria in both Asian and White patients. Overall, these findings highlight Nefecon's efficacy and tolerability across different racial and ethnic groups.
Indication
TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.
Renseignements importants sur la sécurité
Contre-indications: TARPEYO est contre-indiqué chez les patients présentant une hypersensibilité au budésonide ou à l'un des composants de TARPEYO. Des réactions d'hypersensibilité graves, y compris l'anaphylaxie, se sont produites avec d'autres formulations de budésonide.
Avertissements et précautions
Hypercorticisme et suppression de l'axe surrénalien : When corticosteroids are used chronically, systemic effects such as hypercorticism and adrenal suppression may occur. Corticosteroids can reduce the response of the hypothalamus-pituitary-adrenal (HPA) axis to stress. In situations where patients are subject to surgery or other stress situations, supplementation with a systemic corticosteroid is recommended. When discontinuing therapy or switching between corticosteroids, monitor for signs of adrenal axis suppression.
Les patients présentant une insuffisance hépatique modérée à sévère (classes Child-Pugh B et C respectivement) pourraient présenter un risque accru d'hypercorticisme et de suppression de l'axe surrénalien en raison d'une exposition systémique accrue au budésonide oral. Évitez l'utilisation chez les patients présentant une insuffisance hépatique sévère (classe C de Child-Pugh). Surveiller l'augmentation des signes et/ou symptômes d'hypercorticisme chez les patients présentant une insuffisance hépatique modérée (classe B de Child-Pugh).
Risques d'immunosuppression : Patients who are on drugs that suppress the immune system are more susceptible to infection than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible patients or patients on immunosuppressive doses of corticosteroids. Avoid corticosteroid therapy in patients with active or quiescent tuberculosis infection; untreated fungal, bacterial, systemic viral, or parasitic infections, or ocular herpes simplex. Avoid exposure to active, easily transmitted infections (e.g., chicken pox, measles). Corticosteroid therapy may decrease the immune response to some vaccines.
Autres effets des corticostéroïdes : TARPEYO est un corticostéroïde disponible par voie systémique et devrait provoquer des effets indésirables associés. Surveiller les patients souffrant d'hypertension, de prédiabète, de diabète sucré, d'ostéoporose, d'ulcère gastroduodénal, de glaucome ou de cataracte, ou ayant des antécédents familiaux de diabète ou de glaucome, ou présentant toute autre affection dans laquelle les corticostéroïdes peuvent avoir des effets indésirables.
Effets indésirables: In clinical studies, the most common adverse reactions with TARPEYO (occurring in ≥5% of TARPEYO treated patients, and ≥2% higher than placebo) were peripheral edema (17%), hypertension (12%), muscle spasms (12%), acne (11%), headache (10%), upper respiratory tract infection (8%), face edema (8%), weight increased (7%), dyspepsia (7%), dermatitis (6%), arthralgia (6%), and white blood cell count increased (6%).
Interactions médicamenteuses: Le budésonide est un substrat du CYP3A4. Évitez l'utilisation avec des inhibiteurs puissants du CYP3A4, tels que le kétoconazole, l'itraconazole, le ritonavir, l'indinavir, le saquinavir, l'érythromycine et la cyclosporine. Eviter l'ingestion de jus de pamplemousse avec TARPEYO. La consommation de jus de pamplemousse, qui inhibe l'activité du CYP3A4, peut augmenter l'exposition systémique au budésonide.
Utilisation dans des populations spécifiques
Grossesse: Les données disponibles provenant de séries de cas publiées, d'études épidémiologiques et d'analyses sur l'utilisation du budésonide par voie orale chez les femmes enceintes n'ont pas identifié de risque associé au médicament de malformations congénitales majeures, de fausse couche ou d'autres conséquences indésirables pour la mère ou le fœtus. Il existe des risques pour la mère et le fœtus associés à l'IgAN. Les nourrissons exposés aux corticostéroïdes in utero, y compris le budésonide, présentent un risque d'hyposurrénalisme.
S'il te plait regarde Informations de prescription complètes.
À propos de TARPEYO
TARPEYO is an oral 4mg delayed release formulation of budesonide, designed to remain intact until it reaches the ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum, including the Peyer's patches, which are responsible for the production of galactose-deficient IgA1 antibodies (Gd-Ag1) causing IgA nephropathy.
À propos de l'étude NeflgArd
NefIgArd was a global, Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of TARPEYO 16 mg once daily vs placebo in adult patients with primary IgAN (N=364) as an addition to optimized RASi therapy. Patients were randomized 1:1 to receive 16 mg/day oral capsules of TARPEYO or matching placebo for 9 months, followed by a 15-month observational follow-up period without the study drug.
The primary efficacy endpoint was time-weighted average of eGFR over 2 years. The time-weighted average of eGFR over 2 years showed a statistically significant treatment benefit with TARPEYO versus placebo (difference 5•05 mL/min per 1•73 m² [95% CI 3•24 to 7•38], p<0•0001).
The favorable effect of TARPEYO on eGFR was seen by Month 3 (the earliest assessment) and did not appear to increase in magnitude over two years. At the end of Year 2, there was a 5.9 mL/min/1.73 m2 difference in the mean change from baseline in eGFR between TARPEYO and placebo (95% CI: 3.3 to 8.5 mL/min/1.73 m2; p<0.0001). The effect on kidney function seen during the 9-month treatment period persisted following completion of treatment through the end of the study but the overall effect on the long-term rate of decline has not been established.
The most common adverse reactions with TARPEYO (occurring in ≥5% of TARPEYO treated patients and ≥2% higher than placebo) were peripheral edema (17%), hypertension (12%), muscle spasms (12%), acne (11%), headache (10%), upper respiratory tract infection (8%), face edema (8%), weight increase (7%), dyspepsia (7%), dermatitis (6%), arthralgia (6%), and white blood cell count increase (6%).
À propos de la néphropathie primaire à immunoglobuline A
Primary immunoglobulin A nephropathy (IgA nephropathy or IgAN or Berger's Disease) is a rare, progressive, chronic autoimmune disease that attacks the kidneys and occurs when galactose-deficient IgA1 is recognized by autoantibodies, creating IgA1 immune complexes that become deposited in the glomerular mesangium of the kidney.This deposition in the kidney can lead to progressive kidney damage and potentially a clinical course resulting in end- stage renal disease. IgAN most often develops between late teens and late 30s.
Pour plus d'informations, s'il vous plaît contacter:
Åsa Hillsten, responsable des relations internationales et du développement durable, Calliditas
Tél : +46 76 403 35 43, Email : [email protected]
Les informations ont été envoyées pour publication, par l'intermédiaire des personnes de contact indiquées ci-dessus, le 18 avril 2023, à 13.00 h XNUMX CET.
Ces informations vous ont été fournies par Cision http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-therapeutics-presents-additional-data-analyses-from-the-phase-3-neflgard-trial-of-nefecon,c3963340
Les fichiers suivants sont disponibles pour le téléchargement:
https://mb.cision.com/Main/16574/3963340/2740596.pdf | PR_CALT-WCN_ENG |
View original content:https://www.prnewswire.com/news-releases/calliditas-therapeutics-presents-additional-data-analyses-from-the-phase-3-neflgard-trial-of-nefecon-in-primary-iga-nephropathy-at-the-isn-world-congress-of-nephrology-2024-302120857.html
SOURCE Calliditas Thérapeutique